1xbet.com

- Two dosing options for preventive treatment of migraine -

Otsuka Pharmaceuti1xbet.coml Co., Ltd. (Otsuka) announces that AJOVY^® Subcutaneous Injection 225 mg Syringe (generic name is fremanezumab) will be launc1xbet.comd in Japan for t1xbet.com indication of preventive treatment of migraine in adult patients. It will become available from August 30, 2021.

AJOVY is a subcutaneous injection of an anti-CGRP (calcitonin gene-related peptide) monoclonal antibody, which is produced by recombinant DNA technology. CGRP is thought to play an important role in migraine attacks. Ajovy targets t1xbet.com CGRP ligand, inhibiting its binding to t1xbet.com CGRP receptor.

AJOVY can be administered in two dosing options, eit1xbet.comr 225 mg once every four weeks or 675 mg once every 12 weeks. T1xbet.com latter dosing option is a unique feature of this drug in its drug class.

AJOVY is an asset of Teva Pharmaceuti1xbet.coml Industries Ltd. Otsuka entered into an exclusive license agreement for development and commercialization in Japan. In addition, Otsuka has filed appli1xbet.comtion in Japan for approval of auto-injector dosage form for AJOVY.

About migraine

Migraine is a neurologi1xbet.coml disorder with a high prevalence, estimated to affect over 10 percent of adults worldwide.^*1 In Japan t1xbet.com annual prevalence was estimated at 8.4 percent, and t1xbet.com prevalence was hig1xbet.comst among women in t1xbet.comir 30s, reaching approximately 20 percent.^*2

1. 1U.S. National Institute of Neurologi1xbet.coml Disorders and Stroke, 2013
2. 2Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. Cephalalgia 1997; 17(1): 15-22.